163 related articles for article (PubMed ID: 37052729)
1. Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Hanley MJ; Kerstein D; Tugnait M; Narasimhan N; Marbury TC; Venkatakrishnan K; Gupta N
Invest New Drugs; 2023 Jun; 41(3):402-410. PubMed ID: 37052729
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.
Gupta N; Hanley MJ; Griffin RJ; Zhang P; Venkatakrishnan K; Sinha V
Clin Pharmacokinet; 2023 Aug; 62(8):1063-1079. PubMed ID: 37493887
[TBL] [Abstract][Full Text] [Related]
3. Effect of severe renal impairment on the pharmacokinetics of brigatinib.
Gupta N; Hanley MJ; Kerstein D; Tugnait M; Narasimhan N; Marbury TC; Venkatakrishnan K
Invest New Drugs; 2021 Oct; 39(5):1306-1314. PubMed ID: 33742299
[TBL] [Abstract][Full Text] [Related]
4. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
5. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors.
Hanley MJ; D'Arcangelo M; Felip E; Garrido P; Zhu J; Ye M; Vranceanu F; Gupta N
J Clin Pharmacol; 2023 May; 63(5):583-592. PubMed ID: 36579743
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Xu Y; Izumi R; Nguyen H; Kwan A; Kuo H; Madere J; Slatter JG; Podoll T; Vishwanathan K; Marbury T; Smith W; Preston RA; Sharma S; Ware JA
J Clin Pharmacol; 2022 Jun; 62(6):812-822. PubMed ID: 34897701
[TBL] [Abstract][Full Text] [Related]
8. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
Marzin K; Kretschmar G; Luedtke D; Kraemer S; Kuelzer R; Schlenker-Herceg R; Schmid U; Schnell D; Dallinger C
J Clin Pharmacol; 2018 Mar; 58(3):357-363. PubMed ID: 29106740
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
12. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
13. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
[TBL] [Abstract][Full Text] [Related]
15. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Venkatakrishnan K; Sonnichsen D; Kerstein D; Dorer DJ; Narasimhan N
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
[TBL] [Abstract][Full Text] [Related]
16. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
[TBL] [Abstract][Full Text] [Related]
17. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
18. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
20. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]